Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Aromatase inhibitors provide improved efficacy compared to tamoxifen
January 5th, 2006
Aromatase inhibitors provide improved efficacy compared to tamoxifen in the adjuvant setting. "Approximately three-quarters of all invasive breast tumors are estrogen and/or progesterone receptor-positive. The selective estrogen receptor modulator tamoxifen has been the preferred endocrine therapy for almost four decades," investigators in Belgium report. "One of the most significant advances in endocrine therapy for women after menopause with early breast cancer is the introduction of third-generation aromatase inhibitors as an alternative or as an additional treatment to tamoxifen therapy," remarked L. Morales and colleagues. "In making a choice...
Source: Women's Health Weekly (2006-01-05)
|
